The Study of Tadalafil and Tamsulosin as Monotherapy for Lower Urinary Tract Symptoms Due to Benign Hyperplasia of Prostate

Abstract

Introduction: Benign Prostate Hyperplasia (BPH) is the most prevalent benign disease in males with diverse LUTS. It is the fourth most prominent condition among men aged ≥50 years and accounts for 80% of men aged ≥70 years. According to available data, the prevalence of BPH surged from 25% in the 40-49 age group to 80% in the 70-79 age group. Clinically, BPH causes LUTS and its symptoms, such as storage (impaired bladder emptying, urinary frequency, nocturia, urinary urgency, and urge incontinence), voiding (urinary incontinence, a restricted urinary stream), and postmicturition, which can impair patients' quality of life. Materials and methods: We analysed 120 patients of BPH (Benign Prostatic Hyperplasia) with LUTS (Lower Urinary Tract Symptoms) with baseline parameters as international prostate symptom score (IPSS), QMAX (maximum urinary flow velocity), PVR (Post Voidal Residual urine volume), for a period of 12 months. They were divided in to two groups, one group receiving only alpha blockers, other group receiving only PDE -5 inhibitor (Phosphodiesterase type 5 inhibitor/PDE-5I) tadalafil in treatment of LUTS due to BPH. These patients were reviewed at 1, 3, 6 months interval with above mentioned parameters. Results: Of the 120 patients taken up for the study, 60 in each group, only 110 patients completed the study. (54 patients in alpha blockers group and 56 patients in PDE-5 inhibitors group). Both groups were reviewed with mentioned parameters. Conclusion: PDE-5 inhibitor (Tadalafil) should be preferred over alpha blockers in treating LUTS (Lower Urinary Tract Symptoms) due to BPH (Benign Prostatic Hyperplasia) as PDE-5 inhibitors are found to be more efficacious than alpha blocker with lesser incidences of side-effects.